

<b>NAME</b>	<b>: Mrs. PALLAVI SETHI</b>		
<b>AGE/ GENDER</b>	<b>: 44 YRS/FEMALE</b>	<b>PATIENT ID</b>	<b>: 1803520</b>
<b>COLLECTED BY</b>	<b>: SURJESH</b>	<b>REG. NO./LAB NO.</b>	<b>: 012503240030</b>
<b>REFERRED BY</b>	<b>: LOOMBA HOSPITAL (AMBALA CANTT)</b>	<b>REGISTRATION DATE</b>	<b>: 24/Mar/2025 10:01 AM</b>
<b>BARCODE NO.</b>	<b>: 01527658</b>	<b>COLLECTION DATE</b>	<b>: 24/Mar/2025 10:42AM</b>
<b>CLIENT CODE.</b>	<b>: KOS DIAGNOSTIC LAB</b>	<b>REPORTING DATE</b>	<b>: 24/Mar/2025 03:09PM</b>
<b>CLIENT ADDRESS</b>	<b>: 6349/1, NICHOLSON ROAD, AMBALA CANTT</b>		

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

## ENDOCRINOLOGY

### THYROID FUNCTION TEST: TOTAL

TRIIODOTHYRONINE (T3): SERUM <i>by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)</i>	0.912	ng/mL	0.35 - 1.93
THYROXINE (T4): SERUM <i>by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)</i>	6.04	µgm/dL	4.87 - 12.60
THYROID STIMULATING HORMONE (TSH): SERUM <i>by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)</i>	5.165	µIU/mL	0.35 - 5.50

3rd GENERATION, ULTRASENSITIVE

#### INTERPRETATION:

TSH levels are subject to circadian variation, reaching peak levels between 2-4 a.m and at a minimum between 6-10 pm. The variation is of the order of 50%.Hence time of the day has influence on the measured serum TSH concentrations. TSH stimulates the production and secretion of the metabolically active hormones, thyroxine (T4)and triiodothyronine (T3).Failure at any level of regulation of the hypothalamic-pituitary-thyroid axis will result in either underproduction (hypothyroidism) or overproduction(hyperthyroidism) of T4 and/or T3.

CLINICAL CONDITION	T3	T4	TSH
Primary Hypothyroidism:	Reduced	Reduced	Increased (Significantly)
Subclinical Hypothyroidism:	Normal or Low Normal	Normal or Low Normal	High
Primary Hyperthyroidism:	Increased	Increased	Reduced (at times undetectable)
Subclinical Hyperthyroidism:	Normal or High Normal	Normal or High Normal	Reduced

#### LIMITATIONS:-

1. T3 and T4 circulates in reversibly bound form with Thyroid binding globulins (TBG),and to a lesser extent albumin and Thyroid binding Pre Albumin so conditions in which TBG and protein levels alter such as pregnancy, excess estrogens, androgens, anabolic steroids and glucocorticoids may falsely affect the T3 and T4 levels and may cause false thyroid values for thyroid function tests.
2. Normal levels of T4 can also be seen in Hyperthyroid patients with :T3 Thyrotoxicosis, Decreased binding capacity due to hypoproteinemia or ingestion of certain drugs (e.g.: phenytoin , salicylates).
3. Serum T4 levels in neonates and infants are higher than values in the normal adult , due to the increased concentration of TBG in neonate serum.
4. TSH may be normal in central hypothyroidism , recent rapid correction of hyperthyroidism or hypothyroidism , pregnancy , phenytoin therapy.

TRIIODOTHYRONINE (T3)		THYROXINE (T4)		THYROID STIMULATING HORMONE (TSH)	
Age	Refferance Range (ng/mL)	Age	Refferance Range ( µg/dL)	Age	Reference Range ( µIU/mL)
0 - 7 Days	0.20 - 2.65	0 - 7 Days	5.90 – 18.58	0 - 7 Days	2.43 - 24.3
7 Days - 3 Months	0.36 - 2.59	7 Days - 3 Months	6.39 - 17.66	7 Days - 3 Months	0.58 - 11.00
3 - 6 Months	0.51 - 2.52	3 - 6 Months	6.75 – 17.04	3 Days – 6 Months	0.70 - 8.40



*[Signature]*

DR.VINAY CHOPRA  
CONSULTANT PATHOLOGIST  
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

*[Signature]*

DR.YUGAM CHOPRA  
CONSULTANT PATHOLOGIST  
MBBS , MD (PATHOLOGY)




<b>NAME</b>	: <b>Mrs. PALLAVI SETHI</b>		
<b>AGE/ GENDER</b>	: 44 YRS/FEMALE	<b>PATIENT ID</b>	: 1803520
<b>COLLECTED BY</b>	: SURJESH	<b>REG. NO./LAB NO.</b>	: <b>012503240030</b>
<b>REFERRED BY</b>	: LOOMBA HOSPITAL (AMBALA CANTT)	<b>REGISTRATION DATE</b>	: 24/Mar/2025 10:01 AM
<b>BARCODE NO.</b>	: 01527658	<b>COLLECTION DATE</b>	: 24/Mar/2025 10:42AM
<b>CLIENT CODE.</b>	: KOS DIAGNOSTIC LAB	<b>REPORTING DATE</b>	: 24/Mar/2025 03:09PM
<b>CLIENT ADDRESS</b>	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		


Test Name		Value		Unit	Biological Reference interval
6 - 12 Months	0.74 - 2.40	6 - 12 Months	7.10 – 16.16	6 – 12 Months	0.70 - 7.00
1 - 10 Years	0.92 - 2.28	1 - 10 Years	6.00 - 13.80	1 – 10 Years	0.60 - 5.50
11- 19 Years	0.35 - 1.93	11 - 19 Years	4.87- 13.20	11 – 19 Years	0.50 – 5.50
> 20 years (Adults)	0.35 - 1.93	> 20 Years (Adults)	4.87 - 12.60	> 20 Years (Adults)	0.35– 5.50
RECOMMENDATIONS OF TSH LEVELS DURING PREGNANCY ( $\mu$ U/mL)					
1st Trimester		0.10 – 2.50			
2nd Trimester		0.20 – 3.00			
3rd Trimester		0.30 – 4.10			

- INCREASED TSH LEVELS:**
- 1.Primary or untreated hypothyroidism may vary from 3 times to more than 100 times normal depending upon degree of hypofunction.
  - 2.Hypothyroid patients receiving insufficient thyroid replacement therapy.
  - 3.Hashimotos thyroiditis
  - 4.DRUGS: Amphetamines, iodine containing agents & dopamine antagonist.
  - 5.Neonatal period, increase in 1st 2-3 days of life due to post-natal surge
- DECREASED TSH LEVELS:**
- 1.Toxic multi-nodular goiter & Thyroiditis.
  - 2.Over replacement of thyroid hormone in treatment of hypothyroidism.
  - 3.Autonomously functioning Thyroid adenoma
  - 4.Secondary pituitary or hypothalamic hypothyroidism
  - 5.Acute psychiatric illness
  - 6.Severe dehydration.
  - 7.DRUGS: Glucocorticoids, Dopamine, Levodopa, T4 replacement therapy, Anti-thyroid drugs for thyrotoxicosis.
  - 8.Pregnancy: 1st and 2nd Trimester





DR.VINAY CHOPRA  
CONSULTANT PATHOLOGIST  
MBBS, MD (PATHOLOGY & MICROBIOLOGY)



DR.YUGAM CHOPRA  
CONSULTANT PATHOLOGIST  
MBBS , MD (PATHOLOGY)



<b>NAME</b>	<b>: Mrs. PALLAVI SETHI</b>		
<b>AGE/ GENDER</b>	<b>: 44 YRS/FEMALE</b>	<b>PATIENT ID</b>	<b>: 1803520</b>
<b>COLLECTED BY</b>	<b>: SURJESH</b>	<b>REG. NO./LAB NO.</b>	<b>: 012503240030</b>
<b>REFERRED BY</b>	<b>: LOOMBA HOSPITAL (AMBALA CANTT)</b>	<b>REGISTRATION DATE</b>	<b>: 24/Mar/2025 10:01 AM</b>
<b>BARCODE NO.</b>	<b>: 01527658</b>	<b>COLLECTION DATE</b>	<b>: 24/Mar/2025 10:42AM</b>
<b>CLIENT CODE.</b>	<b>: KOS DIAGNOSTIC LAB</b>	<b>REPORTING DATE</b>	<b>: 24/Mar/2025 02:35PM</b>
<b>CLIENT ADDRESS</b>	<b>: 6349/1, NICHOLSON ROAD, AMBALA CANTT</b>		

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

**ESTRADIOL (E2)**

ESTRADIOL (E2): SERUM by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)	56	pg/mL	<b>FEMALE FOLLICULAR PHASE:</b> 19.5 - 144.2 <b>FEMALE MID CYCLE PHASE:</b> 63.9 - 356.7 <b>FEMALE PRE OVULATORY PHASE:</b> 136.0 - 251.0 <b>FEMALE LUTEAL PHASE:</b> 55.8 - 214.2 <b>POST MENOPAUSAL:</b> < 50.0
---	----	-------	---

**INTERPRETATION:**

OTHER MATERNAL FACTORS AND PREGNANCY	UNITS	RANGE
Hormonal Contraceptives	pg/mL	15.0 – 95.0
1st Trimester (0 – 12 Weeks)	pg/mL	38.0 – 3175.0
2nd Trimester (13 – 28 Weeks)	pg/mL	678.0 – 16633.0
3rd Trimester (29 – 40 Weeks)	pg/mL	43.0 – 33781.0
Post Menopausal	Pg/mL	< 50.0
<b>MALES:</b>	pg/mL	< 40.0

1. Estrogens are involved in development and maintenance of the female phenotype, germ cell maturation, and pregnancy. They also are important for many other, nongender-specific processes, including growth, nervous system maturation, bone metabolism/remodeling, and endothelial responsiveness.

2. E2 is produced primarily in ovaries and testes by aromatization of testosterone.


3. Small amounts are produced in the adrenal glands and some peripheral tissues, most notably fat. E2 levels in premenopausal women fluctuate during the menstrual cycle.


4. They are lowest during the early follicular phase. E2 levels then rise gradually until 2 to 3 days before ovulation, at which stage they start to increase much more rapidly and peak just before the ovulation-inducing luteinizing hormone (LH)/follicle stimulating hormone (FSH) surge at 5 to 10 times the early follicular levels. This is followed by a modest decline during the ovulatory phase. E2 levels then increase again gradually until the midpoint of the luteal phase and thereafter decline to trough, early follicular levels.

**INDICATIONS FOR ASSAY: -**

1. Evaluation of hypogonadism and oligo-amenorrhea in females.
2. Assessing ovarian status, including follicle development, for assisted reproduction protocols (eg, in vitro fertilization)
3. In conjunction with luteinizing hormone measurements, monitoring of estrogen replacement therapy in hypogonadal premenopausal women
4. Evaluation of feminization, including gynecomastia, in males.
5. Diagnosis of estrogen-producing neoplasms in males, and, to a lesser degree, females
6. As part of the diagnosis and work-up of precocious and delayed puberty in females, and, to a lesser degree, males



  
**DR. VINAY CHOPRA**  
 CONSULTANT PATHOLOGIST  
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)

  
**DR. YUGAM CHOPRA**  
 CONSULTANT PATHOLOGIST  
 MBBS, MD (PATHOLOGY)



<b>NAME</b>	<b>: Mrs. PALLAVI SETHI</b>		
<b>AGE/ GENDER</b>	<b>: 44 YRS/FEMALE</b>	<b>PATIENT ID</b>	<b>: 1803520</b>
<b>COLLECTED BY</b>	<b>: SURJESH</b>	<b>REG. NO./LAB NO.</b>	<b>: 012503240030</b>
<b>REFERRED BY</b>	<b>: LOOMBA HOSPITAL (AMBALA CANTT)</b>	<b>REGISTRATION DATE</b>	<b>: 24/Mar/2025 10:01 AM</b>
<b>BARCODE NO.</b>	<b>: 01527658</b>	<b>COLLECTION DATE</b>	<b>: 24/Mar/2025 10:42AM</b>
<b>CLIENT CODE.</b>	<b>: KOS DIAGNOSTIC LAB</b>	<b>REPORTING DATE</b>	<b>: 24/Mar/2025 02:35PM</b>
<b>CLIENT ADDRESS</b>	<b>: 6349/1, NICHOLSON ROAD, AMBALA CANTT</b>		

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

7. As part of the diagnosis and work-up of suspected disorders of sex steroid metabolism,eg:aromatase deficiency and 17 alpha-hydroxylase deficiency
8. As an adjunct to clinical assessment,imaging studies and bone mineral density measurement in the fracture risk assessment of postmenopausal women,and,to a lesser degree,older men
9. Monitoring low-dose female hormone replacement therapy in post-menopausal women
10. Monitoring antiestrogen therapy (eg, aromatase inhibitor therapy).
- CAUSES FOR INCREASED E2 LEVELS:**
1. High androgen levels caused by tumors or androgen therapy (medical or sport performance enhancing),with secondary elevations in E1 and E2 due to aromatization
2. Obesity with increased tissue production of E1
3. Decreased E1 and E2 clearance in liver disease
4. Estrogen producing tumors
5. Estrogen Ingestion





DR.VINAY CHOPRA  
CONSULTANT PATHOLOGIST  
MBBS, MD (PATHOLOGY & MICROBIOLOGY)



DR.YUGAM CHOPRA  
CONSULTANT PATHOLOGIST  
MBBS , MD (PATHOLOGY)



**NAME** : Mrs. PALLAVI SETHI  
**AGE/ GENDER** : 44 YRS/FEMALE **PATIENT ID** : 1803520  
**COLLECTED BY** : SURJESH **REG. NO./LAB NO.** : 012503240030  
**REFERRED BY** : LOOMBA HOSPITAL (AMBALA CANTT) **REGISTRATION DATE** : 24/Mar/2025 10:01 AM  
**BARCODE NO.** : 01527658 **COLLECTION DATE** : 24/Mar/2025 10:42AM  
**CLIENT CODE.** : KOS DIAGNOSTIC LAB **REPORTING DATE** : 24/Mar/2025 05:40PM  
**CLIENT ADDRESS** : 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

### ANTI MULLERIAN HORMONE (AMH) GEN II

ANTI MULLERIAN HORMONE (AMH) GEN II: SERUM 0.12 ng/mL 0.02 - 6.35  
 by ECLIA (ELECTROCHEMILUMINESCENCE IMMUNOASSAY)

#### INTERPRETATION:-

A Correlation of FERTILITY POTENTIAL and AMH levels are :

OVARIAN FERTILITY POTENTIAL	AMH VALUES IN (ng/mL)
OPTIMAL FERTILITY:	4.00 – 6.80 ng/mL
SATISFACTORY FERTILITY:	2.20 – 4.00 ng/mL
LOW FERTILITY:	0.30 – 2.20 ng/mL
VERY LOW/UNDETECTABLE:	0.00 – 0.30 ng/mL
HIGH LEVEL:	>6.8 ng/mL (PCOD/GRANULOSA CELL TUMOUR)

Anti Mullerian Hormone (AMH) is also known as Mullerian Inhibiting Substance provided by sertoli cells of the testis in males and by ovarian granulose cells in females upto antral stage in females.

#### IN MALES:

1.It is used to evaluate testicular presence and function in infants with intersex conditions or ambiguous genitalia, and to distinguish between cryptorchidism and anorchia in males

#### IN FEMALES:

- 1.During reproductive age, follicular AMH production begins during the primary stage, peaks in preantral stage & has influence on follicular sensitivity to FSH which is important in selection for follicular dominance. AMH levels thus represents the pool or number of primordial follicles but not the quality of oocytes. AMH does not vary significantly during menstrual cycle & hence can be measured independently of day of cycle.
- 2.Polycystic ovarian syndrome can elevate AMH 2 to 5 fold higher than age specific reference range & predict anovulatory, irregular cycles, ovarian tumours like Granulosa cell tumour are often associated with higher AMH levels.
- 3.Obese women are often associated with diminished ovarian reserve and can have 65% lower mean AMH levels than non-obese women.
- 4.In females , AMH levels do not change significantly throughout the menstrual cycle and decrease with age.
- 5.Assess Ovarian Reserve - correlates with the number of antral follicles in the ovaries.
- 6.Evaluate fertility potential and ovarian response in IVF- Women with low AMG levels are more likely to be poor ovarian responders.
- 7.Assess the condition of Polycystic Ovary and premature ovarian failure.

A combination of Age, Ultrasound markers-Ovarian Volume and Antral Follicle Count, AMH and FSH levels are useful for optimal assessment of ovarian reserve. Studies in various fertility clinics are ongoing to establish optimal AMH concentration for predicting response to invitro fertilization, however, given below is suggested interpretative reference.

AMH levels (ng/mL)	Suggested patient	Anticipated Antral	Anticipated FSH levels	Anticipated Response
--------------------	-------------------	--------------------	------------------------	----------------------



*[Signature]*

DR.VINAY CHOPRA  
CONSULTANT PATHOLOGIST  
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

*[Signature]*

DR.YUGAM CHOPRA  
CONSULTANT PATHOLOGIST  
MBBS, MD (PATHOLOGY)



<b>NAME</b>	: Mrs. PALLAVI SETHI		
<b>AGE/ GENDER</b>	: 44 YRS/FEMALE	<b>PATIENT ID</b>	: 1803520
<b>COLLECTED BY</b>	: SURJESH	<b>REG. NO./LAB NO.</b>	: 012503240030
<b>REFERRED BY</b>	: LOOMBA HOSPITAL (AMBALA CANTT)	<b>REGISTRATION DATE</b>	: 24/Mar/2025 10:01 AM
<b>BARCODE NO.</b>	: 01527658	<b>COLLECTION DATE</b>	: 24/Mar/2025 10:42AM
<b>CLIENT CODE.</b>	: KOS DIAGNOSTIC LAB	<b>REPORTING DATE</b>	: 24/Mar/2025 05:40PM
<b>CLIENT ADDRESS</b>	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name		Value	Unit	Biological Reference interval
	Categorization for fertility based on AMH for age group (20 to 45 yrs)	Follicle counts	(day 3)	to IVF/COH cycle
Below 0.3	Very low	Below 4	Above 20	Negligible/Poor
0.3 to 2.19	Low	4 - 10	Usually 16 - 20	Reduced
2.19 to 4.00	Satisfactory	11 - 25	Within reference range or between 11 - 15	Safe/Normal
Above 4.00	Optimal	Upto 30 and Above	Within reference range or between 11 – 15 or Above 15	Possibly Excessive

**INCREASED:**  
 1.Polycystic ovarian syndrome (most common)  
 2. Ovarian Tumour: Granulosa cell tumour

**DECREASED:**  
 1.Anorchia , Abnormal or absence of testis in males  
 2.Pseudohermaphroditism  
 3.Post Menopause

**NOTE:**  
 1.AMH measurement alone is seldom suffcient for diagnosis and results should be interpreted in the light of clinical finding and other relevant test such as ovarian ultrasonography(In fertility applications); abdominal or testicular ultrasound(intersex or testicular function applications); measurement of sex steroids (estradiol,Progesterone,Testosterone),FSH, Inhibin B (For fertility), and Inhibin A and B (for tumour work up).  
 2.Conversion of AMH grom ng/mL to pmol/L can be performed by using equation 1 ng/mL = 7.14 pmol/L

\*\*\* End Of Report \*\*\*





DR.VINAY CHOPRA  
CONSULTANT PATHOLOGIST  
MBBS, MD (PATHOLOGY & MICROBIOLOGY)



DR.YUGAM CHOPRA  
CONSULTANT PATHOLOGIST  
MBBS , MD (PATHOLOGY)

